

WuXi AppTec (603259 CH)

To navigate macro uncertainties with a good start in 1Q25

WuXi AppTec reported impressive 1Q25 financial results. Revenue increased by 21.0% YoY to RMB9.65bn, with revenue from continuing operations rising by 23.1% YoY to RMB9.39bn. Adjusted non-IFRS net profit surged by 40.0% YoY to RMB2.68bn. Both revenue and net profit continued the quarterly improvement trend seen throughout 2024, which further accelerated significantly in 1Q25. As of the end of 1Q25, the Company's backlog grew by 47.1% YoY to RMB52.33bn. Despite ongoing macro uncertainties, mgmt. has reaffirmed its full-year guidance, projecting a 10–15% YoY increase in revenue from continuing operations and expansion in the adjusted non-IFRS net profit margin.

- TIDES business gained momentum with strong growth. WuXi AppTec's TIDES business experienced strong growth 1Q25, with revenue soaring 187.6% YoY to RMB2.24bn, an acceleration from the 70.1% growth in 2024. According to mgmt., the growth was driven by the ramp-up of new capacities and contributions from oral GLP-1 programs. TIDES backlog more than doubled, increasing by 105.5% YoY as of 1Q25, providing a solid foundation for sustained growth. The Company remains on track to expand its peptide capacity to over 100k liters by the end of 2025. Hence, Mgmt. continued to expect TIDES revenue to grow more than 60% YoY in 2025.
- Early-stage business remained under pressure with signs of moderate recovery. Revenue from Biology segment grew 8.2% YoY in 1Q25, marking a second consecutive quarter of positive growth, indicating a recovery in client demand for drug discovery services. In Chemistry segment, small-molecule drug discovery revenue declined 7.1% YoY, an improvement from the 28.7% YoY drop in 2024. Testing segment remained affected by pricing pressure. Lab testing revenue slid 4.9% YoY (vs. -8.0% YoY in 2024), with safety assessment revenue falling 7.8% YoY (vs. -13.0% YoY in 2024). Mgmt. noted that pricing appeared to have reached a trough, although a meaningful recovery will still take time.
- Strengthening shareholder returns amid market uncertainties. WuXi AppTec's Board of Directors has proposed a series of shareholder return initiatives, including maintaining a 30% annual cash dividend payout ratio, issuing a one-time RMB1bn special dividend in 2025, introducing the interim dividend plan in 2025, and repurchasing and cancelling RMB1bn A-shares (announced on March 17). In addition, the Company announced a second RMB1bn A-share repurchase and cancellation plan on April 8, which has now commenced. Combined, the proposed dividends and share repurchase programs total nearly RMB6bn, equivalent to 62% of 2024 attributable net profit, underscoring WuXi AppTec's strong commitment to shareholder return.
- Maintain BUY. Due to the macro uncertainties such as the US-China trade war, we revise down forecasts and now expect revenue from continuing operation business to grow by 13.3%/14.9%/15.9% YoY and adjusted non-IFRS net income to grow by 9.7%/17.5%/15.9% YoY in 2025E/ 26E/ 27E, respectively (previously: 14.4%/15.2%/16.3% and 11.7%/19.0%/+16.1% YoY). We thus cut our DCF-based TP from RMB94.05 to RMB77.22 (WACC: 9.42%, terminal growth: 2.00%; both unchanged). Our estimates are higher than Bloomberg consensus, reflecting our confidence in earnings resilience.

Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	40,341	39,241	42,974	49,386	57,220
YoY growth (%)	2.5	(2.7)	9.5	14.9	15.9
Adjusted net profit (RMB m	10,854	10,583	11,610	13,645	15,809
YoY growth (%)	15.5	(2.5)	9.7	17.5	15.9
EPS (Adjusted) (RMB)	3.70	3.67	4.02	4.72	5.47
Consensus EPS (RMB)	na	na	3.99	4.50	5.09
P/E (Adjusted) (x)	16.3	16.5	15.0	12.8	11.0

Source: Company data, Bloomberg, CMBIGM estimates. Estimates refer to continuing operations.

BUY (Maintain)

Target Price RMB77.22
(Previous TP RMB94.05)
Up/Downside 27.7%
Current Price RMB60.45

China Healthcare

Jill WU, CFA (852) 3900 0842 jillwu@cmbi.com.hk

Benchen HUANG, CFA huangbenchen@cmbi.com.hk

Stock Data

174,410.4
2,670.3
70.00/36.87
2885.2

Source: FactSet

Shareholding Structure

Ge Li and concerted parties	20.5%
HK investors	21.9%

Source: Company report

Share Performance

	Absolute	Relative
1-mth	-10.8%	-9.1%
3-mth	9.2%	8.0%
6-mth	13.0%	13.0%

Source: FactSet

12-mth Price Performance



Source: FactSet



Figure 1: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	42,974	49,386	57,220	43,367	49,961	58,103	-0.91%	-1.15%	-1.52%
Gross Profit	18,655	21,543	25,051	19,400	22,542	26,362	-3.84%	-4.43%	-4.97%
Operating Profit	13,371	15,222	17,785	13,516	15,739	18,450	-1.08%	-3.28%	-3.60%
Non-IFRS net profit	11,610	13,645	15,809	11,823	14,075	16,339	-1.80%	-3.06%	-3.25%
Non-IFRS EPS (RMB)	4.02	4.72	5.47	4.09	4.87	5.66	-1.80%	-3.06%	-3.25%
Gross Margin	43.41%	43.62%	43.78%	44.73%	45.12%	45.37%	-1.32ppt	-1.50ppt	-1.59ppt
Operating Margin	31.11%	30.82%	31.08%	31.17%	31.50%	31.75%	-0.05ppt	-0.68ppt	-0.67ppt
Net Margin	27.02%	27.63%	27.63%	27.26%	28.17%	28.12%	-0.25ppt	-0.54ppt	-0.49ppt

Source: Company data, CMBIGM estimates

Note: CMBIGM estimates refer to continuing operations of WuXi AppTec.

Figure 2: CMBIGM estimates vs consensus

	CMBIGM			Consensus			Diff (%)		
RMB mn	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	42,974	49,386	57,220	42,785	48,223	54,264	0.44%	2.41%	5.45%
Gross Profit	18,655	21,543	25,051	18,365	20,866	23,579	1.58%	3.24%	6.24%
Operating Profit	13,371	15,222	17,785	13,440	15,259	17,241	-0.52%	-0.24%	3.16%
Non-IFRS net profit	11,610	13,645	15,809	11,516	12,983	14,694	0.82%	5.10%	7.59%
Non-IFRS EPS (RMB)	4.02	4.72	5.47	3.99	4.50	5.09	0.76%	4.92%	7.61%
Gross Margin	43.41%	43.62%	43.78%	42.92%	43.27%	43.45%	+0.49ppt	+0.35ppt	+0.33ppt
Operating Margin	31.11%	30.82%	31.08%	31.41%	31.64%	31.77%	-0.30ppt	-0.82ppt	-0.69ppt
Net Margin	27.02%	27.63%	27.63%	26.92%	26.92%	27.08%	+0.10ppt	+0.71ppt	+0.55ppt

Source: Company data, Bloomberg, CMBIGM estimates
Note: CMBIGM estimates refer to continuing operations of WuXi AppTec.



Figure 3: Valuation on risk-adjusted DCF valuation

DCF Valuation (in Rmb mn)	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
EBIT	15,346	16,022	18,585	20,072	21,477	22,766	23,904	24,860	25,606	26,118
Tax rate	15.22%	15.22%	15.22%	15.22%	15.22%	15.22%	15.22%	15.22%	15.22%	15.22%
EBIT*(1-tax rate)	13,009	13,583	15,756	17,017	18,208	19,300	20,265	21,076	21,708	22,142
+ D&A	2,961	3,465	3,770	4,034	4,276	4,489	4,669	4,809	4,905	4,954
- Change in working capital	843	-1,199	-1,465	-1,568	-1,662	-1,745	-1,815	-1,869	-1,907	-1,926
- Capex	-7,500	-6,500	-5,000	-5,000	-5,000	-5,000	-5,000	-5,000	-5,000	-5,000
FCFF	9,314	9,349	13,061	14,482	15,822	17,045	18,119	19,016	19,707	20,171
Terminal value										277,283

Terminal growth rate	2.00%
WACC	9.42%
Cost of Equity	12.00%
Cost of Debt	4.00%
Equity Beta	0.90
Risk Free Rate	3.00%
Market Risk Premium	10.00%
Target Debt to Asset ratio	30.00%
Effective Corporate Tax Rate	15.00%
PV of terminal value (RMB mn)	112,708
Total PV (RMB mn)	204,986
Net debt (RMB mn)	-18,015
Equity value (RMB mn)	223,001
# of shares (mn)	2,888
Price per share (RMB per share)	77.22

Source: CMBIGM estimates

Figure 4: Sensitivity analysis of DCF model

				WACC		
		8.42%	8.92%	9.42%	9.92%	10.42%
	3.00%	98.99	90.72	83.74	77.78	72.62
	2.50%	93.74	86.46	80.24	74.87	70.19
Terminal	2.00%	89.30	82.81	77.22	72.34	68.04
growth rate	1.50%	85.50	79.66	74.57	70.10	66.14
	1.00%	82.21	76.91	72.24	68.12	64.43

Source: CMBIGM estimates



Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Revenue	39,355	40,341	39,241	42,974	49,386	57,220
Cost of goods sold	(24,677)	(23,729)	(22,965)	(24,319)	(27,844)	(32,169)
Gross profit	14,678	16,612	16,277	18,655	21,543	25,051
Operating expenses	(5,372)	(5,318)	(5,164)	(5,285)	(6,320)	(7,266)
Selling expense	(732)	(701)	(745)	(859)	(1,037)	(1,202)
Admin expense	(2,826)	(2,879)	(2,879)	(2,793)	(3,358)	(3,891)
R&D expense	(1,614)	(1,441)	(1,239)	(1,289)	(1,531)	(1,717)
Others	(200)	(297)	(301)	(343)	(394)	(456)
Operating profit	9,306	11,294	11,112	13,371	15,222	17,785
Gain/loss on financial assets at FVTPL	770	(38)	187	200	200	200
Investment gain/loss	188	234	604	1,500	200	200
Net Interest income/(expense)	248	338	787	433	472	492
Other income/expense	106	4	(1,150)	275	400 46 404	400
Pre-tax profit	10,618	11,832	11,540	15,778	16,494	19,078
Income tax After tax profit	(1,716) 8,903	(2,132) 9,700	(1,972) 9,568	(2,696) 13,082	(2,819) 13,675	(3,260) 15,818
Minority interest	(89)	(94)	(117)	(161)	(168)	(194)
Net profit	8,814	9,607	9,450	12,921	13,508	15,623
Adjusted net profit	9,399	10,854	10,583	11,610	13,645	15,809
Gross dividends	2,644	2,882	2,835	3,876	4,052	4,687
BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Current assets	23,997	30,422	38,690	39,516	46,557	57,023
Cash & equivalents	7,986	13,764	18,322	21,764	26,884	35,001
Account receivables	6,047	7,922	8,044	7,653	8,795	10,190
Inventories	5,669	4,736	5,400	5,367	6,145	7,099
Prepayment	291	244	226	226	226	226
Financial assets at FVTPL	2	11	1,234	1,234	1,234	1,234
Other current assets	4,003	3,746	5,464	3,273	3,273	3,273
Non-current assets	40,693	43,247	41,636	47,568	50,872	52,421
PP&E	14,171	17,190	18,784	23,733	27,178	28,819
Deferred income tax	492	367	473	473	473	473
Investment in JVs & assos	1,203	2,216	2,326	2,326	2,326	2,326
Intangibles	1,785	1,864	1,575	1,410	1,246	1,081
Goodwill	1,822	1,821	972	972	972	972
Financial assets at FVTPL	8,954	8,626	8,943	10,518	10,918	11,318
Other non-current assets	12,265	11,164	8,562	8,135	7,758	7,431
Total assets	64,690	73,669	80,326	87,085	97,428	109,443
Current liabilities	14,499	14,756	16,226	14,779	15,500	16,385
Short-term borrowings	3,874	3,667	1,243	243	243	243
Account payables	1,659	1,645	1,764	2,183	2,904	3,788
Tax payable	882	1,374	1,211	1,211	1,211	1,211
Other current liabilities	8,084	8,070	12,008	11,143	11,143	11,143
Non-current liabilities	3,264	3,396	5,014	5,014	5,014	5,014
Long-term borrowings	279	687	2,960	2,960	2,960	2,960
Bond payables	502	0	0	0	0	0
Obligations under finance leases	984	1,099	547	547	547	547
Other non-current liabilities Total liabilities	1,499 17,764	1,610 18,152	1,508 21,240	1,508 19,793	1,508 20,514	1,508 21,399
		•				
Share capital	2,961	2,969	2,888	2,888	2,888	2,888
Capital surplus	26,512	28,401	24,338	33,383	42,838	53,774
Other reserves	17,118	23,753	31,407	30,407	30,407	30,407
Total shareholders equity	46,590	55,122	58,633	66,678	76,133	87,069
Minority interest	337	395	453	613	781	975
Total equity and liabilities	64,690	73,669	80,326	87,085	97,428	109,443



CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	10,618	11,832	11,540	15,778	16,494	19,078
Depreciation & amortization	1,718	2,288	2,769	2,897	3,351	3,606
Tax paid	(1,716)	(2,132)	(1,972)	(2,696)	(2,819)	(3,260)
Change in working capital	(298)	(105)	(926)	843	(1,199)	(1,465)
Others	294	1,504	996	(1,762)	(626)	(647)
Net cash from operations	10,616	13,387	12,407	15,060	15,201	17,311
Investing						
Capital expenditure	(9,966)	(5,517)	(4,003)	(7,500)	(6,500)	(5,000)
Acquisition of subsidiaries/ investments	(161)	(22)	0	0	0	0
Net proceeds from disposal of short-term	82	(2,321)	(2,013)	0	0	0
investments Others	355	299	498	1,326	0	0
Net cash from investing	(9,690)	(7,561)	(5,518)	(6,174)	(6,500)	(5,000)
-	(-,,	()	(-,,	(, ,	(3,233)	(-//
Financing Dividend paid	(1,598)	(2,756)	(3,085)	(3,444)	(3,581)	(4,195)
Net borrowings	1,668	178	3,320	(1,000)	0	0
Proceeds from share issues	150	247	196	0	0	0
Others	(1,497)	(1,610)	(4,264)	(1,000)	0	0
Net cash from financing	(1,278)	(3,941)	(3,832)	(5,444)	(3,581)	(4,195)
Net change in cash						
Cash at the beginning of the year	8,175	7,984	10,001	18,322	21,764	26,884
Exchange difference	161	132	388	0	0	0
Cash at the end of the year	7,984	10,001	13,445	21,764	26,884	35,001
GROWTH	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Revenue	71.8%	2.5%	(2.7%)	9.5%	14.9%	15.9%
Gross profit	76.6%	13.2%	(2.0%)	14.6%	15.5%	16.3%
Operating profit	110.9%	21.4%	(1.6%)	20.3%	13.9%	16.8%
Net profit	72.9%	9.0%	(1.6%)	36.7%	4.5%	15.7%
Adj. net profit	83.2%	15.5%	(2.5%)	9.7%	17.5%	15.9%
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Gross profit margin	37.3%	41.2%	41.5%	43.4%	43.6%	43.8%
Operating margin	23.6%	28.0%	28.3%	31.1%	30.8%	31.1%
Adj. net profit margin	23.9%	26.9%	27.0%	27.0%	27.6%	27.6%
Return on equity (ROE)	20.7%	18.9%	16.6%	20.6%	18.9%	19.1%
GEARING/LIQUIDITY/ACTIVITIES	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec	4	4>	4>	4>		4
Net debt to equity (x)	(0.1)	(0.2)	(0.2)	(0.3)	(0.3)	(0.4)
Current ratio (x)	1.7	2.1	2.4	2.7	3.0	3.5
Receivable turnover days	49.7	63.2	74.3	65.0	65.0	65.0
Inventory turnover days	85.6 75.5	80.0	80.6	80.6	80.6	80.6
Payable turnover days	75.5	75.6	74.6	74.6	74.6	74.6
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
P/E (adjusted)	18.9	16.3	16.5	15.0	12.8	11.0
P/B	3.8	3.2	3.0	2.6	2.3	2.0
P/CFPS	16.7	13.2	14.1	11.6	11.5	10.1
Div yield (%)	1.5	1.6	1.6	2.2	2.3	2.7

 $Source: Company\ data,\ CMBIGM\ estimates.\ Note:\ The\ calculation\ of\ net\ cash\ includes\ financial\ assets.$



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

: Stock with potential return of over 15% over next 12 months BUY HOLD Stock with potential return of +15% to -10% over next 12 months SELL NOT RATED : Stock with potential loss of over 10% over next 12 months

: Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.